PMID- 33386466
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20240506
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 70
IP  - 7
DP  - 2021 Jul
TI  - The subtle interplay between gamma delta T lymphocytes and dendritic cells: is 
      there a role for a therapeutic cancer vaccine in the era of combinatorial 
      strategies?
PG  - 1797-1809
LID - 10.1007/s00262-020-02805-3 [doi]
AB  - Human gamma delta (gammadelta) T cells represent heterogeneous subsets of unconventional 
      lymphocytes with an HLA-unrestricted target cell recognition. gammadelta T cells display 
      adaptive clonally restricted specificities coupled to a powerful cytotoxic 
      function against transformed/injured cells. Dendritic cells (DCs) are documented 
      to be the most potent professional antigen-presenting cells (APCs) able to induce 
      adaptive immunity and support the innate immune response independently from T 
      cells. Several data show that the cross-talk of gammadelta T lymphocytes with DCs can 
      play a crucial role in the orchestration of immune response by bridging innate to 
      adaptive immunity. In the last decade, DCs, as well as gammadelta T cells, have been of 
      increasing clinical interest, especially as monotherapy for cancer immunotherapy, 
      even though with unpredictable results mainly due to immune suppression and/or 
      tumor-immune escape. For these reasons, new vaccine strategies have to be 
      explored to reach cancer immunotherapy's full potential. The effect of DC-based 
      vaccines on gammadelta T cell is less extensively investigated, and a combinatorial 
      approach using DC-based vaccines with gammadelta T cells might promote a strong synergy 
      for long-term tumor control and protection against escaping tumor clones. Here, 
      we discuss the therapeutic potential of the interaction between DCs and gammadelta T 
      cells to improve cancer vaccination. In particular, we describe the most relevant 
      and updated evidence of such combinatorial approaches, including the use of 
      Zoledronate, Interleukin-15, and protamine RNA, also looking towards future 
      strategies such as CAR therapies.
FAU - Galati, Domenico
AU  - Galati D
AUID- ORCID: 0000-0001-5613-9149
AD  - Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology 
      and Developmental Therapeutics, Istituto Nazionale Tumori-IRCCS-Fondazione G. 
      Pascale, Naples, Italy. d.galati@istitutotumori.na.it.
FAU - Zanotta, Serena
AU  - Zanotta S
AD  - Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology 
      and Developmental Therapeutics, Istituto Nazionale Tumori-IRCCS-Fondazione G. 
      Pascale, Naples, Italy.
FAU - Bocchino, Marialuisa
AU  - Bocchino M
AD  - Department of Clinical Medicine and Surgery, Universita degli Studi di Napoli 
      Federico II, Naples, Italy.
FAU - De Filippi, Rosaria
AU  - De Filippi R
AD  - Department of Clinical Medicine and Surgery, Universita degli Studi di Napoli 
      Federico II, Naples, Italy.
FAU - Pinto, Antonio
AU  - Pinto A
AD  - Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology 
      and Developmental Therapeutics, Istituto Nazionale Tumori-IRCCS-Fondazione G. 
      Pascale, Naples, Italy.
LA  - eng
GR  - M2/8-OG/Ministero della Salute/
PT  - Journal Article
PT  - Review
DEP - 20210101
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cancer Vaccines)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*administration & dosage/immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunity, Innate/*immunology
MH  - Immunotherapy/*methods
MH  - Lymphocyte Activation/*immunology
MH  - Neoplasms/immunology/*therapy
MH  - Receptors, Antigen, T-Cell, gamma-delta/*immunology/metabolism
PMC - PMC10991494
OTO - NOTNLM
OT  - Cancer immunotherapies
OT  - Combinatorial strategies
OT  - DC-based vaccines
OT  - Dendritic cells
OT  - gammadelta T cells
COIS- All the other authors declare that they have no conflict of interest.
EDAT- 2021/01/03 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/01/01
CRDT- 2021/01/02 05:19
PHST- 2020/06/30 00:00 [received]
PHST- 2020/11/21 00:00 [accepted]
PHST- 2021/01/03 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/01/02 05:19 [entrez]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.1007/s00262-020-02805-3 [pii]
AID - 2805 [pii]
AID - 10.1007/s00262-020-02805-3 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2021 Jul;70(7):1797-1809. doi: 
      10.1007/s00262-020-02805-3. Epub 2021 Jan 1.